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 Background: 
Little is known about the possible influence of demographic and histological risk factors on the 
survival amongst patients with esophageal and gastric cancer. Based on available registry and 
follow-up information, this study compares 1-5 year survival rate of gastric and esophageal 
cancer. 
Objectives: 
This study compares 1-5 year survival rate of gastric and esophageal cancer. 
Patients and Methods: 
Through a concurrent (prospective) cohort study, all 366 patients with definite diagnosis of 
esophageal and gastric cancer who had been hospitalized at the Towhid Hospital, Sanandaj city, 
Kurdistan province western Iran during a five-year period from 2006 onwardS were recruited. 
The survival time of patients stratified by this grouping method were analyzed by Kaplan-Meier 
analysis and Cox regression. 
Results: 
Amongst 366 patients, 23 had esophageal adenocarcinoma, 94 esophageal squamous-cell 
carcinoma and 239 had gastric adenocarcinoma. Age at diagnosis (P = < 0.001) and tumor grad 
(P = 0.008), practice treatment (P = < 0.001) had significant association with the survival rates 
variation in patients with esophageal but not with gastric cancer patients. The five-year survival 
rates (by year) in esophageal cancer were 49%, 27%, 24%, 22% and 19%, respectively and in 
gastric cancer were 41%, 17%, 13%, 10% and 5.4%, respectively. 
Conclusions: 
 Major differences between these cancers were seen in the survival rates of patients and the 
incidence classified by sex. Ages at diagnosis, histological types were prognostic factors for 
survival in patients with esophageal cancer and no in gastric cancer. 
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 1. Background 
Gastric cancer remains a major cause of cancer mortality. Since last decades, gastric cancer 
mortality rate has decreased globally (1). However, still remains major public health concern 
with a poor prognosis and a high mortality (2). In contrast, the incidence of esophageal cancer is 
increasing (3). In the United States, the incidence of esophageal cancer has shown a six-fold rise 
caused by increasing the incidence of esophageal adenocarcinoma (4). In Europe there has also 
been an increase in the incidence of esophageal adenocarcinoma in men, but not in women (5). A 
similar pattern has already been found in Iran (6). The disease is highly lethal, with overall five -
year survival rates less than 10%. The high mortality is due to the late onset of symptoms (7). In 
Ardabil province 2007, one- and five-years survival rates in patients with upper gastrointestinal 
cancer were 40.5% and 0.8% respectively (8). Geographic variation and temporal trends in the 
epidemiology of esophageal and gastric cancers vary according to tumor morphology and organ 
subsite. Geographic variations in IR Iran show that incidence and mortality of upper GI 
(Gastrointestinal) cancers is higher in West and North West regions and in the Kurdistan 
province in particular (9).  
2. Ojbectives 
Based on available registry and follow-up information, this study compares 1-5 year survival rate 
of gastric and esophageal cancer. 
3. Patients and Methods 
23.1. Source of Data 
Data were sourced mainly from the patient reports of pathology laboratories and hospital 
database record. Through a concurrent (prospective) study using censes method; all eligible 
patients with upper GI cancers (134 esophagus, and 249 gastric cancer) who had been 
 hospitalized at the Towhid Hospital, Sanandaj city, Kurdistan province western IR Iran were 
recruited. Inclusion criteria were patients with definite diagnosis of upper GI cancer during a 
five-year period from 2006 onward. Samples were coded under the direct supervision of clinical 
pathologists according to the International Classification of Diseases for Oncology (10). Clinical 
data such as practice treatment were obtained through a structured questionnaire and the patients’ 
clinical records. Vital status and date of death were determined through the by official death 
certificates, with a maximum follow-up of 90 months. Survival time (in months) was calculated 
from the date of diagnosis through the date of death or last follow-up. A failure was defined as 
death by any cause during the follow-up period and patients alive at the end of the follow-up 
period were censored. Overall, 17 patients were excluded from the analyses according to 
exclusion criteria (8 patients lost to follow-up, 9 illegible data, and 3 patients due to migration). 
Overall, 366 (127 esophagus, and 239 gastric cancer) patients were enrolled. Clinical and 
pathologic variables, which were sub-layered into age, gender, setting, histological type of tumor 
and practice treatment were entered into parametric regression models (by considering and not 
considering heterogeneity) for multivariate analysis in order to assess the relationships between 
the characteristics and prognostic factors for survivors. The present study was approved (Code 
No: 91002, Date: 22.08.2012) by the Ilam University of Medical Sciences, Ethics Committee on 
considering of publication data result in general. 
3.2. Statistical Analysis 
The Kaplan Meier and Log rank statistic methods were used to compare survival rates in 
different subgroups. Using life table, survival rates and survival density function was assessed at 
year intervals. The Breslow (Generalized wilcoxon) statistics was used to compare median 
survival time in three age groups. The Cox hazards regression analysis was also used to 
 investigate the effect of the variables and adjusting the effect of demographical and pathological 
variables on survival. The Graphical (diagram Log (S) t vs. time) and analytical (Time-Varying 
covariate) methods was applied to test the appropriateness of Cox’s proportional hazard (11). 
The Multiple Cox regression analysis was used to identify independent predictors for patient 
survival using a backward stepwise approach with an entry limit of P < 0.1 and a removal limit 
of P < 0.05. The survival time of patients stratified by this grouping method were analyzed by 
the Kaplan-Meier analysis and Cox regression as described earlier. T tests, chi-square tests and 
Fisher’s exact test were used to compare patient characteristics and tumor factors between the 
populations. All statistical analyses were performed using SPSS16.0. 
4. Results 
Out of the 366 study patients, 23 (18.1%) were diagnosed with esophageal adenocarcinoma 
(AC), 94 patients (74.0%) with esophageal squamous- cell carcinoma (SCC) and 239 with 
gastric cancer. Adenocarcinoma intestinal type was the predominant histological type of gastric 
tumor129 (54%). Mean age ± standard deviation (SD) at diagnosis in patients with gastric cancer 
was 68.8 ± 11.97 years and 65.38 ± 11.62 in esophageal cancer (P = < 0.01) (Table 1). 
 
Table 1. Characteristic of the Patients With Gastric and Esophageal Cancers 
Factors Gastric Cancer, No (%) Esophageal Cancer, No (%) 
Gender   
Male 178 (74.5) 70 (55.1) 
Female 61 (25.5) 57 (44.9) 
Age   
45 > 9 (3.8) 11 (8.7) 
46-65 90 (37.7) 54 (42.5) 
66 < 139 (58.8) 42 (48.8) 
Setting   
City 120 (50.2) 82 (64.6) 
Village 119 (49.8) 45 (35.4) 
Histological type 
a
   
 AC/Intestinal 129 (54.0) 23 (18.1) 
SCC/Diffuse 84 (35.1) 94 (74.0) 
Other 26 (10.9) 10 (7.9) 
Histology grade   
Poor 28 (11.8) 16 (12.6) 
Moderate 25 (10.5) 35 (27.6) 
Well 31 (13.0) 42 (48.8) 
No difference 154 (64.4) 14 (11.0) 
Practice treatment   
Surgery 19 (12.7) 15 (11.8) 
Chemotropic 53 (35.3) 30 (23.6) 
Radiotherapy 4 (1.7) 7 (5.5) 
a
 Esophageal cancer (Adenocarcinoma type (AC), squamous- cell carcinoma type (SCC) and 
other (unknown type)); Gastric cancer (Intestinal type, Diffuse type and other (unknown type)) 
 
A majority of patients were male and older than 65 years in gastric cancer and 46-65 years age 
group in esophageal cancer. The median ± (SD) survival rate for patients with esophageal cancer 
was 10.0 ± 1.05 months and for those with gastric cancer were 11 ± 0.46 months. In those with 
esophageal cancer, patients with the histopathology of “SCC” had the lowest survival rate 
(median: 7 months); other cases lived more than 13 months after the diagnosis. Selected 
characteristics of the patients are shown in (Table 2 and 3). 
 
Table 2. Median of Survival of the Patients With Esophageal Cancer 
Factors 
Median of Survival, (CI 
95%) 
P value 
Gender   
Male 10 (7.97 - 12.03) 
0.480 
Female 12 (6.46 - 17.54) 
Age   
45 > 25 (10.94 - 31.33) 
< 0.001 46 - 65 18 (10.94 - 25.06) 
66 < 6 (4.6 - 7.4) 
Setting   
City 10 (8.05 - 11.95) 
0.148 
Village 14 (10.05 - 17.95) 
 Histological type 
a
    
AC 7 (4.18 - 9.82) 
< 0.001 SCC  13 (9.34 - 16.66) 
Other  10 (7.93 - 12.07) 
Histology grade   
Poor 7 (1.12 - 12.88) 
0.008 
Moderate 22 (6.06 - 37.94) 
Well 9 (6.80 - 11.20) 
No difference 12 (7.41 - 16.59) 
Practice treatment   
Surgery 12 (4.42 - 19.57) 
< 0.001 Chemotropic 5 (3.92 - 6.07) 
Radiotherapy 5 (2.91 - 7.09) 
a
 Adenocarcinoma type (AC), squamous- cell carcinoma type (SCC) and other (unknown type) 
 
Table 3. Median of Survival of the Patients With Gastric Cancer 
Factors 
Median of Survival, (CI 
95%) 
P value 
Gender   
Male 11 (9.54 - 12.06) 
0.361 
Female 13 (11.46 - 14.86) 
Age   
45 > 12 (7.98 - 16.02) 
0.220 46 - 65 12 (8.54 - 16.46) 
66 < 10 (8.71 - 11.29) 
Setting   
City 11 (9.47 - 12.53) 
0.198 
Village 10 (10.08 - 11.92) 
Histological type   
Intestinal  11 (9.82 - 12.18) 
0.611 diffuse 13 (11.21 - 14.79) 
Other 10 (9.19 - 10.81) 
Histology grade   
Poor 10 (7.06 - 12.94) 
0.309 
Moderate 16 (13.94 - 8.06) 
Well 13 (9.17 - 16.83) 
No difference 11 (10.09 - 11.91) 
Practice treatment   
Surgery 12 (8.90 - 15.10) 
0.367 Chemotropic 9 (6.48 - 15.52) 
Radiotherapy 7 (4.45 - 9.55) 
 
 Gender and setting of patients had no significant effects on survival rate variation in univariate 
analysis in both cancers. Age at diagnosis (P = < 0.001), practice treatment (P = < 0.001), 
histology grad (P = 0.008) and tumor histology (P = 0.004) were significant association on the 
survival rates variation in patients with esophageal and no significant association in gastric 
cancer patients (Figure 1). 
 
Figure 1 The Associations Between Demographic and Histological Factors and Survival in 
Esophageal and Gastric Cancer Patients 
 
A) By Histological of Tumor in Esophageal Cancer 
 
  
B) By Histological of Tumor in Gastric Cancer 
 
 
C) By Age at Diagnosis in Esophageal Cancer 
 
  
D) By Age at Diagnosis Gastric Cancer 
 
Potential prognostic factors in patients with gastric cancer showed that tumor histology, 
histology grad, practice treatment gender, age, and place of residence on the prognosis was not 
significant in a multivariate model adjusted for follow-up time. For esophageal cancer Cox-
regression analysis using demographic and histological factors 45 > year as reference revealed 
that patients whose 46-65 year at diagnosis (HR = 3.43, 95%, CI = 1.03-11.41, P = 0.044), 66 < 
year (HR = 9.78, 95% CI = 2.93-32.64, P = < 0.001) had an increased risk for disease 
progression and death. Cox-regression analysis for poorly grade as reference revealed that 
patients whose tumors with moderately differentiate (HR = 0.52, 95%, CI = 0.25 - 1.07, P = 
0.078), well differentiate (HR = 0.98, 95%, CI = 0.51-1.85, P = 0.951) had a decreased risk for 
death from esophagus cancer. Cox regression coefficient ( ) analysis shows patient with tumor 
locate in middle of esophageal (  = -0.91) and upper of esophageal (  = -0.13) have lower death 
rates compression to tumors that located in lower of esophagus. Similar results were obtained for 
tumor grade (Table 4). 
  
Table 4. Multivariate Cox Regression Analyses for Patients With Esophageal Cancer 
Characteristics β HR (95% CI) P value 
Age - overall < 0.001 
45 > reference 1 reference 
46 - 65 1.23 3.43 (1.03-11.41) 0.044 
< 65 2.28 9.78 (2.93-32.64) < 0.001 
Histology grade - overall 0.085 
Poor reference 1 reference 
Moderate -0.64 0.52 (0.25-1.07) 0.078 
Well -0.02 0.98 (0.51-1.85) 0.951 
Location of tumor - overall 0.009 
Lower reference 1 reference 
Middle -0.91 0.40 (0.22-0.73) 0.003 
Upper -0.13 0.53 (0.33-0.85) 0.009 
 
The five-year survival rates (by year) in esophageal cancer were 49%, 27%, 24%, 22% and 19% 
respectively and in gastric cancer were 41%, 17%, 13%, 10% and 5.4% respectively (Figure 2). 
 
 
Figure 2. 1 - 5 Year Survival Rates of Gastric and Esophageal Cancer 
 
 Figure 2 shows that patients with esophageal cancer had a better survival than those with gastric 
cancer (P = 0.305). Overall one-year survival in the cases of esophageal cancer included in the 
present study was 49.0%, with survival rates being higher in the group of women compared to 
the men (19.7% versus 13.8%) (P = 0.48). Similar results were obtained for patient with gastric 
cancer (Table 5). 
 
Table 5. 1 - 5 Year Survival Rates of Gastric and Esophageal Cancer Related to Demographic 
and Histological Factors 
Survival Variables 
Cancer 
Survival rates, (%)  
1-year 2-year  3 -year 4-year  5-year  
Med Tim 
Survival 
By Month 
G
as
tr
ic
 
Gender       
Male 45.1 18.2 13.5 12.6 7.3 11.56 
Female 48.2 21.3 19.7 15.6 15.6 11.90 
Age       
45 > 62.3 46.7 24.2 18.1 13.3 15.00 
46-65 49.3 24.3 17.2 15.3 12.1 12.62 
66 < 43.4 17.1 14.2 11.3 8.5 11.08 
Histological type       
Intestinal 47.3 23.3 18.1 16.3 12.5 11.59 
Diffuse 50.5 7.1 4.0 4.0 4.0 13.78 
Es
o
p
h
ag
e
al
 
Gender    19.5   
Male 46.2 23.3 19.5  13.7 11.27 
Female 52.3 29.7 24.1 19.0 19.0 13.45 
Age       
45 > 80.2 80.2 68.3 68.3 68.3 60.0 
46 - 65 72.1 38.5 31.1 27.2 27.2 20.25 
66 < 24.5 8.3 4.2 4.2 0.0 7.98 
Histological type       
AC 21.2 19.2 5.1 1.2 0.0 7.67 
SCC 56.2 32.1 25.5 22.0 19.0 15.43 
 
5. Discussion 
 Geographic variability in prognosis of gastric cancer patients has been well documented (12, 13). 
The minimum and maximum survival rates have been reported in European countries and East 
Asia respectively (14). Similarly, the five-year survival rates for gastric cancer vary from 10% to 
55% worldwide (15). In IR Iran the prognosis of patients with gastric cancers remains poor (9, 
14) As a result, both diseases are among the deadliest forms of cancer (16). In our study, the 
five-year overall survival rate for patients with esophageal cancer in this population (19%) is 
very poor and women had a better survival rate than men (0.345). This result agrees with a report 
from Europe (17). According to our data, there was significant difference in survival rates 
between patients with SCC and those with AC of the esophagus. These results are in contrast 
with studies in the United Kingdom (1987 to 2000) (18) and Germany (1982 to 2000) (19), 
which showed that AC has a more favorable prognosis than SCC in esophageal cancer patients. 
In general, esophageal cancer five-year survival (19%) was poor, but it was slightly better than 
that for gastric cancer (5.4%) (P = 0.361). These figures are different from those found in the 
countries such as England and South Korea (20, 21). Major differences between these cancers 
were seen in the survival rates of patients and the incidence classified by sex (Table 1). The 
present results showed that patients' gender had no significant impact on survival rate in both 
cancers. Median survival time for man and women for esophageal cancer was (10.0 ± 1.03) and 
(12.0 ± 2.83), respectively and for gastric cancer were (11.0 ± 0.53) and (13.0 ± 0.94), 
respectively. Sex was not an independent prognostic factor in either Chinese patients (p = 0.23) 
(22) or white patients living in the United States (P = 0.28) (23). Overall survival was 
significantly worse only in male white compared with Chinese patients (median survival time, 
12.4 versus 14.5 months, respectively; P < .01) (22), But, some studies have found better 
survival rate for women (24). 
 For esophageal cancer; patients under age 45 had significantly better survival in unvarited 
analysis. The reasons for this are likely to include a combination of better general health, more 
effective response to treatment and earlier diagnosis in younger people overall. Differences in 
underlying tumor biology may also play a part. Previous report indicated better survival in young 
patients (22). On the other hand, some other studies have not same report (16). Cell histology is 
another tumor related factor that might affect patient survival. Our finding is in conformity with 
previous reports showed that better survival for AC of esophagus (25). In this study, the Lauren 
classification (based on tumor histology) did not have prognostic significance for five-year 
survival of gastric cancer patients in either population (log rank = 0.611). Treatment is likely to 
be the greatest determinant of cancer patients’ survival. Surgical results in treatment of 
esophageal cancer have improved significantly over recent years, however. Medical centers now 
report that patients undergoing surgery alone have median survival rates between 13 and 19 
months, 2-year survival rates between 35% and 42%, and 5-year survival rates of 15% to 24% 
(26), in present study in patients that surgery was only option to treatment median of survival 
and 4-year survival rate in esophageal cancer was (12 ± 3.86 month) and (% 21.3), respectively 
(P = < 0.001). In patient that radiation therapy was only option to treatment for esophageal and 
gastric cancer the mean survival rate was (5 ± 1.06 month) and (7 ± 1.29 month), respectively. 
Radiation therapy has been used in the past as a single-modality approach with curative intent. 
However, except for those with very early-stage disease, radiation has had little impact on long-
term survival (27). Chemotherapy has been given preoperatively, postoperatively, or both 
median survival rates were (5 ± 0.548 month) for esophageal and (9 ± 1.28 month) for gastric 
cancer. Multimodality treatment approaches have evolved over recent years in response to the 
frequent loco regional and distant recurrences identified after surgery or radiation therapy alone. 
 The strength of the study was assured by the availability of homogeneous samples data with 
details of tumor histology and pathology, using Cox multiple to adjustment result variables on 
survival and calculation of five survival rates separately for sub-groups analysis. There are 
limitations with the present study in which the survival rate unable to predict future events for a 
particular person. Meanwhile, it was not possible to consider changes in characteristics after 
diagnosis, which may have affected survival. Hospital series often provide more optimistic data; 
there are challenges in interpreting registry information regarding the health care system in IR 
Iran. They are of limited value because of unavoidable selection bias, in particular in case 
selection and patient's characteristics. In conclusions, Gastric and esophageal cancers are 
heterogeneous diseases, but they share important features. They remain clinically asymptomatic 
until late in the disease process with consequent poor prognoses and high mortality rates. This 
study points to differences in disease characteristics and patient factors. Even so, the outcomes of 
these cancers are poor and improvements in diagnosis and management are urgently needed. 
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